Respiratory medicine最新文献

{"title":"Corrigendum to \"Longitudinal Assessment of lung function in patients following COVID-19\" [Respir Med. 243 (2025 Apr 29) 108130. doi: 10.1016/j.rmed.2025.108130. Online ahead of print. PMID: 40311850].","authors":"David A Kaminsky, Jamie Rowell, Katherine Menson, Kevin Hodgdon, Derek Devine, Olivia J Garrow, Cory Raymond, Elise Prehoda, Tessalyn Morrison, Charles G Irvin","doi":"10.1016/j.rmed.2025.108211","DOIUrl":"https://doi.org/10.1016/j.rmed.2025.108211","url":null,"abstract":"","PeriodicalId":21057,"journal":{"name":"Respiratory medicine","volume":" ","pages":"108211"},"PeriodicalIF":3.5,"publicationDate":"2025-06-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144317812","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association between Pan-immune-inflammation value and in-hospital mortality in critically ill patients with Chronic obstructive pulmonary disease: An observational study","authors":"Mohan Giri ,&nbsp;Anju Puri ,&nbsp;Yi Chen ,&nbsp;Yan Liu ,&nbsp;Shuliang Guo","doi":"10.1016/j.rmed.2025.108213","DOIUrl":"10.1016/j.rmed.2025.108213","url":null,"abstract":"<div><h3>Objective</h3><div>This study aimed to examine the relationship between the pan-immune inflammation value (PIV) and mortality in critically ill patients with chronic obstructive pulmonary disease (COPD), highlighting its potential as a prognostic tool for this high-risk group.</div></div><div><h3>Methods</h3><div>This retrospective cohort study utilized data from the MIMIC-IV 2.2 database. Participants were stratified into tertiles based on their PIV levels, with the primary endpoint being in-hospital mortality. Cox proportional hazards regression models were used to analyze the association between PIV and mortality, and Kaplan-Meier survival curves illustrated survival differences among PIV tertiles. Subgroup analyses and interaction tests ensured the robustness of the findings.</div></div><div><h3>Results</h3><div>A total of 3259 critically ill COPD patients were included. The in-hospital and 90-day mortality rates were 15 % and 27.6 %, respectively. Multivariate analysis showed that higher PIV levels were significantly associated with increased in-hospital (HR: 1.08, 95 % CI: 1.02–1.14, P = 0.012) and 90-day mortality (HR: 1.16, 95 % CI: 1.11–1.21, P &lt; 0.001). Patients in the highest tertile of PIV (T3) had a significantly higher risk of mortality compared to those in the lowest tertile (T1). The trend test across tertiles demonstrated a positive association between PIV and mortality risk in all models (P for trend &lt;0.001). Subgroup analyses revealed no significant effect modification except for gender and liver disease.</div></div><div><h3>Conclusion</h3><div>Elevated baseline PIV was independently associated with higher mortality risks in critically ill COPD patients, suggesting its potential as a simple, reliable, and cost-effective prognostic indicator for high-risk patients.</div></div>","PeriodicalId":21057,"journal":{"name":"Respiratory medicine","volume":"245 ","pages":"Article 108213"},"PeriodicalIF":3.5,"publicationDate":"2025-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144288936","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"New reference values for the 6-minute walk distance in a European population across the full adult age range","authors":"Kevin De Soomer ,&nbsp;Kaat Geubels ,&nbsp;Hilbert Mendoza ,&nbsp;Reinier Wener ,&nbsp;Thérèse Lapperre ,&nbsp;Ellie Oostveen","doi":"10.1016/j.rmed.2025.108205","DOIUrl":"10.1016/j.rmed.2025.108205","url":null,"abstract":"<div><h3>Introduction</h3><div>The 6-min walk test (6MWT) is widely used to evaluate functional exercise capacity in individuals of all ages. However, there are currently no widely accepted reference values for the 6-min walk distance (6MWD) in White populations across the full adult age range, as most existing predictions are derived from selected age groups. This study aimed to develop 6MWD reference equations for European populations covering the entire adult lifespan.</div></div><div><h3>Methods</h3><div>Healthy adults, equally distributed for sex and age, performed a single 6MWT according to current guidelines. The effects of sex, age, height, weight and BMI on the 6MWD were analysed.</div></div><div><h3>Results</h3><div>The 6MWT was performed in 212 subjects (51 % females, age: 18–87 yrs). Males walked a greater distance than females with a mean ± SD 6MWD of 697 ± 83 m and 629 ± 72 m, respectively (p &lt; 0.001). In both sexes, the 6MWD was not affected by age below 50 years whereas it declined progressively beyond this age. Height and BMI linearly correlated with the 6MWD in males and females (both p &lt; 0.001) while weight was only related to the 6MWD in males (p = 0.02). A reference equation was developed using stepwise multiple regression, with sex, age, age², height and weight as significant predictors of the 6MWD (R² = 0.548).</div></div><div><h3>Conclusion</h3><div>In the present study, we observed a non-linear ageing effect on the 6MWD throughout adulthood. The developed reference equation accounts for this effect and should be considered in settings where a single 6MWT is performed in European adults of all ages.</div></div>","PeriodicalId":21057,"journal":{"name":"Respiratory medicine","volume":"245 ","pages":"Article 108205"},"PeriodicalIF":3.5,"publicationDate":"2025-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144306967","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"From itchy skin to wheezing: Potential biomarkers and targeted drugs for atopic dermatitis and asthma in children","authors":"Xinyu Zheng ,&nbsp;Han Jiang ,&nbsp;Ruanlin Cui ,&nbsp;Aihua Cai ,&nbsp;Baixin He ,&nbsp;Ailin Tao ,&nbsp;Shan Wang","doi":"10.1016/j.rmed.2025.108212","DOIUrl":"10.1016/j.rmed.2025.108212","url":null,"abstract":"<div><div>Atopic dermatitis (AD) and allergic asthma (AA) are interconnected allergic diseases that frequently co-occur in early childhood, representing a critical sequence in the \"atopic march\". The rising global prevalence of these conditions, driven by environmental factors and epigenetic changes, underscores an urgent clinical need to understand their shared pathogenesis and disrupt disease progression. Evidence implicates multifaceted mechanisms in AD-to-AA progression, including skin barrier dysfunction, type 2 inflammation, microbiome dysbiosis, and systemic immune priming. These pathways not only elucidate the disease continuum but also offer actionable biomarkers for early prediction and targeted interventions. This review synthesizes the epidemiology, mechanistic insights, and translational implications of AD-to-AA progression, advocating for a paradigm shift toward early-risk stratification and precision medicine. By bridging mechanistic discoveries with clinical practice, we aim to guide optimized management and primary prevention, ultimately reducing the global allergy burden.</div></div>","PeriodicalId":21057,"journal":{"name":"Respiratory medicine","volume":"245 ","pages":"Article 108212"},"PeriodicalIF":3.5,"publicationDate":"2025-06-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144302776","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comment on “Long-term air pollution exposure and risk of SARS-CoV-2 infection: A UK-wide cohort study”","authors":"Shu Ran ,&nbsp;Haopeng Li ,&nbsp;Baolin Liu","doi":"10.1016/j.rmed.2025.108209","DOIUrl":"10.1016/j.rmed.2025.108209","url":null,"abstract":"","PeriodicalId":21057,"journal":{"name":"Respiratory medicine","volume":"245 ","pages":"Article 108209"},"PeriodicalIF":3.5,"publicationDate":"2025-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144294858","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical response and remission in patients treated with dupilumab for severe asthma: Results from the nationwide Danish Severe Asthma Register","authors":"Susanne Hansen ,&nbsp;Kjell Erik Julius Håkansson ,&nbsp;Marianne Baastrup Soendergaard ,&nbsp;Anne-Sofie Bjerrum ,&nbsp;Johannes Martin Schmid ,&nbsp;Sofie Lock Johansson ,&nbsp;Linda Makowska Rasmussen ,&nbsp;Claus Rikard Johnsen ,&nbsp;Anna von Bülow ,&nbsp;Barbara Bonnesen ,&nbsp;Niels Steen Krogh ,&nbsp;Ole Hilberg ,&nbsp;Lycely Dongo ,&nbsp;Roxana Vijdea ,&nbsp;Charlotte Suppli Ulrik ,&nbsp;Celeste Porsbjerg","doi":"10.1016/j.rmed.2025.108203","DOIUrl":"10.1016/j.rmed.2025.108203","url":null,"abstract":"<div><h3>Background</h3><div>Randomized clinical trials have demonstrated that dupilumab reduces exacerbations and maintenance oral corticosteroids (mOCS) use in patients with uncontrolled and severe asthma. However, evidence in real-life settings is limited.</div></div><div><h3>Objective</h3><div>This study aimed to evaluate the proportion of patients achieving a clinical response and remission after treatment with dupilumab and identify predictors of response.</div></div><div><h3>Methods</h3><div>We conducted a prospective observational study involving 203 severe asthma patients from the nationwide Danish Severe Asthma Register treated with dupilumab for 12 months. Clinical response to treatment was defined as a 50 % reduction in exacerbations and/or a 50 % reduction in mOCS dose. Clinical remission required meeting all the following criteria: complete cessation of exacerbations, no mOCS use, an Asthma Control Questionnaire (ACQ-6) score &lt;1.50 and forced expiratory volume in 1 s (FEV₁) &gt; 80 % of the predicted value. Predictors of treatment response were identified in a multivariate logistic regression model.</div></div><div><h3>Results</h3><div>After 12 months of dupilumab treatment, 91 % of patients demonstrated a clinical response, and 30 % achieved clinical remission. All patients experienced fewer exacerbations, while patients with a clinical response and those achieving remission also exhibited significant improvements in mOCS dose reduction, FEV₁ %, and ACQ-6 score. Predictors of remission included higher baseline fractional exhaled nitric oxide [OR = 3.82 (95 % CI: 0.90, 16.17)], lower body mass index [OR = 0.82 (95 % CI: 0.71, 0.93) for one unit increase], and the absence of allergic rhinitis [OR = 0.30 (95 % CI: 0.08, 1.11)].</div></div><div><h3>Conclusion</h3><div>In this real-life setting, involving over 200 patients treated with dupilumab for 12 months, 91 % had a clinical response, and 30 % of patients achieved clinical remission. These findings highlight dupilumab's potential in improving outcomes for severe asthma patients.</div></div>","PeriodicalId":21057,"journal":{"name":"Respiratory medicine","volume":"245 ","pages":"Article 108203"},"PeriodicalIF":3.5,"publicationDate":"2025-06-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144294857","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bronchiectasis after allogeneic hematopoietic cell transplantation – an underdiagnosed complication","authors":"Ophir Freund ,&nbsp;Yitzhac Hadad ,&nbsp;Anne Bergeron ,&nbsp;Sabrina Fried ,&nbsp;Gidon Pomerantz ,&nbsp;Avshalom Shaffer ,&nbsp;Dolev Paz ,&nbsp;Nevo Barel ,&nbsp;Tal Moshe Perluk ,&nbsp;Odelia Amit ,&nbsp;Ron Ram ,&nbsp;Amir Bar-Shai","doi":"10.1016/j.rmed.2025.108208","DOIUrl":"10.1016/j.rmed.2025.108208","url":null,"abstract":"<div><h3>Background</h3><div>Bronchiectasis (BE) following allogeneic hematopoietic cell transplantation (allo-HCT) are described in the context of bronchiolitis obliterans syndrome (BOS). However, data on its overall prevalence and characteristics in allo-HCT patients are scarce.</div></div><div><h3>Objectives</h3><div>To assess the prevalence, characteristics, and outcomes of symptomatic new-onset bronchiectasis after allo-HCT.</div></div><div><h3>Methods</h3><div>A prospective database with all subjects that underwent allo-HCT between 2014 and 2022 in a tertiary center was utilized. Chest CT scans of subjects with respiratory symptoms were analyzed and compared to pre-HCT scans for BE. Changes in pulmonary function tests (PFTs) and mortality were compared between patients with and without BE.</div></div><div><h3>Results</h3><div>Overall, 282 subjects underwent allo-HCT and 182 survived at 6 months. Thirty-six patients (20 %) were diagnosed with new-onset BE. Median (IQR) duration from HCT to BE diagnosis was 304 (202–547) days. Of those with BE and serial PFTs, 39 % met the criteria for BOS. Independent predictors for BE included chronic graft vs. host disease (adjusted OR 6.8, 95 % CI 1.34–34.6) and a lower baseline FEV1 % (aOR 0.95, 95 % CI 0.92–0.98). BE was associated with increased hazard of mortality (HR 1.91, 95 % CI 1.1–3.6), validated by an extended cox model and sub-group analyses. Patients meeting the criteria for BOS had lower follow-up PFTs and a higher rate of diffuse distribution of bronchiectasis (67 % vs. 32 %). Moreover, patients with BOS had increased mortality compared to BE not meeting these criteria (HR 3.40, 95 % CI 1.2–9.4).</div></div><div><h3>Conclusions</h3><div>Bronchiectasis is prevalent after allo-HCT with major impact, not solely explained by BOS.</div></div>","PeriodicalId":21057,"journal":{"name":"Respiratory medicine","volume":"245 ","pages":"Article 108208"},"PeriodicalIF":3.5,"publicationDate":"2025-06-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144272373","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Airway Involvement in Pulmonary Sarcoidosis: Clinical and CT Features.","authors":"Ying Zhou, Qian Yao, Xianqiu Chen, Dong Yu, Bing Jie, Elyse E Lower, Robert P Baughman","doi":"10.1016/j.rmed.2025.108207","DOIUrl":"https://doi.org/10.1016/j.rmed.2025.108207","url":null,"abstract":"<p><strong>Background: </strong>Sarcoidosis is a systemic granulomatous disorder with frequent respiratory system involvement, yet comprehensive data on airway abnormalities remain limited. This study aims to assess the prevalence and characteristics of airway involvement in pulmonary sarcoidosis and its correlation with clinical and radiological features.</p><p><strong>Methods: </strong>A retrospective, single-center study was conducted at Shanghai Pulmonary Hospital, including 842 patients diagnosed with pulmonary sarcoidosis between March 2013 and September 2023. Airway abnormalities were identified via bronchoscopy, and clinical, radiological, and pulmonary function data were analyzed.</p><p><strong>Results: </strong>Airway involvement was observed in 27.1% of patients (228/842), with thickening (21.4%), nodularity (11.9%), and plaques (7.2%) being the most common patterns. Patients with airway involvement exhibited higher cough prevalence (67.1% vs. 51.5%, p<0.001), elevated serum angiotensin-converting enzyme (SACE) levels, and more extensive pulmonary parenchymal infiltration on high-resolution computed tomography (HRCT). Cobblestoning, nodularity, and plaques were strongly associated with granuloma detection in endobronchial biopsies.</p><p><strong>Conclusion: </strong>Airway involvement in pulmonary sarcoidosis is associated with more severe symptoms, higher disease activity, and distinct radiological patterns. These findings highlight the interplay between pulmonary parenchymal and airway pathology, warranting further investigation into their relationship.</p>","PeriodicalId":21057,"journal":{"name":"Respiratory medicine","volume":" ","pages":"108207"},"PeriodicalIF":3.5,"publicationDate":"2025-06-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144294856","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"ICS use trajectories in severe asthma patients on benralizumab: real-life data from 3-years follow-up","authors":"Laura Pini ,&nbsp;Marco Caminati ,&nbsp;Matteo Maule ,&nbsp;Diego Bagnasco ,&nbsp;Bianca Beghè ,&nbsp;Benedetta Bondi ,&nbsp;Fulvio Braido ,&nbsp;Paolo Cameli ,&nbsp;Cristiano Caruso ,&nbsp;Claudia Crimi ,&nbsp;Yehia El Masri ,&nbsp;Jordan Giordani ,&nbsp;Gabriella Guarnieri ,&nbsp;Manuela Latorre ,&nbsp;Andrea Mastrototaro ,&nbsp;Francesco Menzella ,&nbsp;Claudio Micheletto ,&nbsp;Alessandro Pini ,&nbsp;Stefano Piras ,&nbsp;Antonio Spanevello ,&nbsp;Roberto Benoni","doi":"10.1016/j.rmed.2025.108198","DOIUrl":"10.1016/j.rmed.2025.108198","url":null,"abstract":"<div><h3>Background</h3><div>Inhaled steroids dose reduction is a relevant goal in severe asthma management.</div></div><div><h3>Research question</h3><div>We aimed to investigate ICS use trajectories and their clinical impact in severe asthma patients on benralizumab over 36 months.</div></div><div><h3>Study design and methods</h3><div>We conducted a retrospective real-life observational study including clinical and inflammatory parameters. Patients were stratified according to ICS dose trends over time: “stable” (same dose at ≥80 % of visits), “decreasing” (≥50 % of visits with lower ICS dose vs baseline), and “increasing” (≥50 % of visits with higher ICS dose vs baseline).</div></div><div><h3>Results</h3><div>92 patients were included. Post-bronchodilation FEV₁ significantly increased over 36 months, while pre-bronchodilation FEV₁ remained stable. An overall statistically significant improvement was observed also for ACT, ACQ, AQLQ and annual exacerbation rate. The probability of decreasing ICS dose was 19.0 % at 12 months and 37.4 % at 36 months. In the decreasing group (30 % of the cohort), baseline blood eosinophil count (BEC) was higher than in the stable group, and BEC suppression over time was greater. The decreasing group was also less frequently treated with OCS at baseline. At 24 months, the stable group showed a greater reduction in OCS use compared to the decreasing group. Across all groups, OCS use dropped from 89.8 % to 4.9 % at 36 months.</div></div><div><h3>Interpretation</h3><div>The findings suggest that ICS tapering is feasible and safe in selected patients under benralizumab therapy.</div></div><div><h3>Conclusions</h3><div>To the best of our knowledge, this is the first real-life study specifically supporting the ICS-sparing effect of benralizumab over a 36-month period.</div></div>","PeriodicalId":21057,"journal":{"name":"Respiratory medicine","volume":"245 ","pages":"Article 108198"},"PeriodicalIF":3.5,"publicationDate":"2025-06-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144294859","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pulmonary Aspergillosis: Epidemiology and unresolved diagnostic challenges - insights from a two-year retrospective cohort study in Marseille","authors":"Thi Quynh Pham ,&nbsp;Léa Delorme ,&nbsp;Sébastien Cortaredona ,&nbsp;Stéphane Ranque ,&nbsp;Estelle Menu","doi":"10.1016/j.rmed.2025.108206","DOIUrl":"10.1016/j.rmed.2025.108206","url":null,"abstract":"<div><h3>Objective</h3><div><em>Aspergillus</em> spp. are ubiquitous fungi that cause invasive pulmonary aspergillosis (IPA), chronic pulmonary aspergillosis (CPA), allergic bronchopulmonary aspergillosis (ABPA), and some other less common forms depending on the immune status of the host. This study aimed to evaluate the epidemiology and clinical diagnosis of <em>Aspergillus</em>-related diseases at the University Hospital of Marseille (AP-HM).</div></div><div><h3>Methods</h3><div>We performed a retrospective cohort study of patients treated at the AP-HM between January 2022 and December 2023. <em>Aspergillus-</em>specific serologic tests (IgG, IgE) and galactomannan antigen (GM) tests were integrated with clinical, imaging data from patients’ medical records. Diagnostic frameworks were established based on the standard diagnostic criteria to identify IPA, CPA, and ABPA.</div></div><div><h3>Results</h3><div>Of 2412 patients with GM testing, 46 (1.9 %) had IPA. Of 2889 patients with <em>Aspergillus</em>-specific IgG testing, 16 (0.6 %) were diagnosed with CPA. Of 1779 patients with <em>Aspergillus</em>-specific IgE testing, 46 (2.6 %) were diagnosed with ABPA. We noted biotherapy (tocilizumab and oblinutuzumab) as potential emerging risk factors for IPA. Strikingly, only 10 of 46 patients with ABPA were treated by physicians, highlighting potential gaps in clinical practice and current diagnostic guidelines. The 3-month case fatality rate was 46.7 % for IPA, 13.3 % for CPA and 0 for APBA. Despite treatment, 13 % of patients with ABPA experienced an exacerbation.</div></div><div><h3>Conclusions</h3><div>This study highlights the prevalence of <em>Aspergillus</em>-related lung disease and the high 3-month mortality rate in IPA and CPA in AP-HM. Discrepancies in ABPA diagnosis highlight the need for improved diagnostic algorithms that better reflect real-world clinical practice and address these challenges.</div></div>","PeriodicalId":21057,"journal":{"name":"Respiratory medicine","volume":"245 ","pages":"Article 108206"},"PeriodicalIF":3.5,"publicationDate":"2025-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144261785","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}